M&A / Deals Avalyn seeks public debut to support new lung drug formulations BioSpaceAnalysts are cautiously optimistic about an IPO rebound for biopharma.M&A / DealsRespiratoryRead full story pharminent April 24, 2026 (Last updated: April 25, 2026) BioSpace Analysts are cautiously optimistic about an IPO rebound for biopharma. M&A / DealsRespiratoryRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Beyond Formulary Access: Building a Scalable Pharmaceutical Manufacturer Commercial Platform for Direct-to-Consumer and Employer ChannelsNext: Pfizer culls early PD-L1 asset after series of clinical wins, deals in cancer Related Stories M&A / Deals Pfizer signs licence agreement with Chai for AI drug discovery pharminent June 5, 2026 M&A / Deals Peptide biotech Parabilis targets up to $476M IPO pharminent June 4, 2026 M&A / Deals Regeneron deepens relationship with CytomX, adding up to $2B and eight targets pharminent June 4, 2026
